

Wolfram Doehner

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1244017/wolfram-doechner-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

262 papers	15,396 citations	63 h-index	117 g-index
296 ext. papers	19,172 ext. citations	6.6 avg, IF	6.3 L-index

#	Paper	IF	Citations
262	Frailty consensus: a call to action. <i>Journal of the American Medical Directors Association</i> , 2013 , 14, 392-7	5.9	1930
261	Plasma cytokine parameters and mortality in patients with chronic heart failure. <i>Circulation</i> , 2000 , 102, 3060-7	16.7	634
260	Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. <i>Circulation</i> , 2002 , 105, 2619-24	16.7	463
259	Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. <i>Circulation</i> , 2003 , 107, 1991-7	16.7	449
258	Nutritional recommendations for the management of sarcopenia. <i>Journal of the American Medical Directors Association</i> , 2010 , 11, 391-6	5.9	387
257	Altered intestinal function in patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 1561-9	15.1	355
256	Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). <i>European Heart Journal</i> , 2013 , 34, 512-9	9.5	345
255	Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 1054-60	15.1	312
254	The relationship between cholesterol and survival in patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2003 , 42, 1933-40	15.1	304
253	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018 , 20, 853-872	12.3	264
252	Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. <i>Journal of Cardiac Failure</i> , 2003 , 9, 29-35	3.3	239
251	Peripheral chemoreceptor hypersensitivity: an ominous sign in patients with chronic heart failure. <i>Circulation</i> , 2001 , 104, 544-9	16.7	220
250	Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 1019-26	15.1	210
249	Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. <i>JACC: Heart Failure</i> , 2015 , 3, 136-45	7.9	190
248	Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. <i>Cardiovascular Research</i> , 2007 , 73, 298-309	9.9	183
247	Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. <i>European Journal of Heart Failure</i> , 2016 , 18, 786-95	12.3	180
246	Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. <i>Journal of the American College of Cardiology</i> , 2001 , 38, 443-52	15.1	179

245	Sarcopenia: A Time for Action. An SCWD Position Paper. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019 , 10, 956-961	10.3	171
244	Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. <i>American Journal of Hematology</i> , 2017 , 92, 1068-1078	7.1	168
243	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. <i>Lancet, The</i> , 2020 , 396, 1895-1904	4.0	162
242	Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. <i>Journal of Cardiac Failure</i> , 2011 , 17, 899-906	3.3	160
241	Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2017 , 19, 821-836	12.3	147
240	Metabolic impairment in heart failure: the myocardial and systemic perspective. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1388-400	15.1	147
239	Overweight and obesity are associated with improved survival, functional outcome, and stroke recurrence after acute stroke or transient ischaemic attack: observations from the TEMPIS trial. <i>European Heart Journal</i> , 2013 , 34, 268-77	9.5	146
238	Stroke induced Sarcopenia: muscle wasting and disability after stroke. <i>International Journal of Cardiology</i> , 2013 , 170, 89-94	3.2	142
237	Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. <i>International Journal of Cardiology</i> , 2012 , 162, 20-6	3.2	139
236	Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. <i>Circulation: Heart Failure</i> , 2010 , 3, 73-81	7.6	136
235	Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2012 , 157, 80-5	3.2	134
234	Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. <i>European Journal of Preventive Cardiology</i> , 2020 , 26(17):1673-1683	3.9	131
233	Anemia and inflammation in COPD. <i>Chest</i> , 2005 , 127, 825-9	5.3	127
232	Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. <i>European Journal of Heart Failure</i> , 2011 , 13, 670-80	12.3	124
231	Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. <i>European Heart Journal</i> , 2014 , 35, 932-41	9.5	117
230	Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 1973-80	15.1	117
229	Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure. <i>European Heart Journal</i> , 2016 , 37, 1684-91	9.5	112
228	Intestinal blood flow in patients with chronic heart failure: a link with bacterial growth, gastrointestinal symptoms, and cachexia. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1092-102	15.1	111

227	Sarcopenia in patients with heart failure with preserved ejection fraction: Impact on muscle strength, exercise capacity and quality of life. <i>International Journal of Cardiology</i> , 2016 , 222, 41-46	3.2	109
226	Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2010 , 12, 484-91	12.3	105
225	Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2011 , 2, 81-86	10.3	101
224	Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. <i>Atherosclerosis</i> , 2015 , 242, 496-503	3.1	100
223	Body weight after stroke: lessons from the obesity paradox. <i>Stroke</i> , 2011 , 42, 3646-50	6.7	94
222	Searching for Atrial Fibrillation Poststroke: A White Paper of the AF-SCREEN International Collaboration. <i>Circulation</i> , 2019 , 140, 1834-1850	16.7	93
221	Muscle wasting in heart failure: An overview. <i>International Journal of Biochemistry and Cell Biology</i> , 2013 , 45, 2257-65	5.6	89
220	The Prevalence of Metabolic Syndrome In Chronic Obstructive Pulmonary Disease: A Systematic Review. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016 , 13, 399-406	2	85
219	Stroke-related sarcopenia: specific characteristics. <i>Journal of the American Medical Directors Association</i> , 2015 , 16, 272-6	5.9	81
218	The obesity paradox in chronic disease: facts and numbers. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2012 , 3, 1-4	10.3	81
217	Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance. <i>American Heart Journal</i> , 2001 , 141, 792-9	4.9	79
216	Heart and brain interaction in patients with heart failure: overview and proposal for a taxonomy. A position paper from the Study Group on Heart and Brain Interaction of the Heart Failure Association. <i>European Journal of Heart Failure</i> , 2018 , 20, 199-215	12.3	77
215	The obesity paradox: weighing the benefit. <i>European Heart Journal</i> , 2010 , 31, 146-8	9.5	77
214	Heat shock protein 70 in patients with chronic heart failure: relation to disease severity and survival. <i>International Journal of Cardiology</i> , 2004 , 96, 397-401	3.2	76
213	Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. <i>Heart Failure Clinics</i> , 2009 , 5, 549-60	3.3	75
212	Cardiac cachexia: hic et nunc. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016 , 7, 246-60	10.3	74
211	Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. <i>Circulation</i> , 2021 , 143, 326-336	16.7	74
210	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 1270-1278	12.3	73

209	Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). <i>European Journal of Heart Failure</i> , 2018 , 20, 1580-1587	12.3	73
208	Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. <i>European Heart Journal</i> , 2007 , 28, 821-8	9.5	72
207	Insulin resistance in moderate chronic heart failure is related to hyperleptinaemia, but not to norepinephrine or TNF-alpha. <i>International Journal of Cardiology</i> , 2002 , 83, 73-81	3.2	69
206	Heart Failure Association/European Society of Cardiology position paper on frailty in patients with heart failure. <i>European Journal of Heart Failure</i> , 2019 , 21, 1299-1305	12.3	68
205	Effect of interleukin-10 on the production of tumor necrosis factor-alpha by peripheral blood mononuclear cells from patients with chronic heart failure. <i>American Journal of Cardiology</i> , 2002 , 90, 384-9	3	68
204	Stroke-heart syndrome: clinical presentation and underlying mechanisms. <i>Lancet Neurology</i> , 2018 , 17, 1109-1120	24.1	68
203	The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the Studies Investigating Co-morbidities Aggravating Heart Failure. <i>International Journal of Cardiology</i> , 2016 , 205, 6-12	3.2	66
202	Sarcopenia in stroke-facts and numbers on muscle loss accounting for disability after stroke. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2011 , 2, 5-8	10.3	66
201	High tumour necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients. <i>Cytokine</i> , 2001 , 15, 80-6	4	66
200	Cardiovascular function and predictors of exercise capacity in patients with colorectal cancer. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1310-9	15.1	63
199	Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2010 , 1, 187-194	10.3	62
198	Anorexia in chronic obstructive pulmonary disease--association to cachexia and hormonal derangement. <i>International Journal of Cardiology</i> , 2007 , 119, 83-9	3.2	62
197	Catabolic signaling and muscle wasting after acute ischemic stroke in mice: indication for a stroke-specific sarcopenia. <i>Stroke</i> , 2014 , 45, 3675-83	6.7	60
196	Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options. <i>Seminars in Nephrology</i> , 2011 , 31, 433-40	4.8	57
195	Sarcopenia, cachexia, and muscle performance in heart failure: Review update 2016. <i>International Journal of Cardiology</i> , 2017 , 238, 5-11	3.2	54
194	Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. <i>European Journal of Heart Failure</i> , 2018 , 20, 1664-1672	12.3	54
193	Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 585-92	15.1	51
192	The relationship between tumor necrosis factor- α brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2010 , 141, 39-43	3.2	51

191	Dysfunction of respiratory muscles in critically ill patients on the intensive care unit. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016 , 7, 403-12	10.3	50
190	Absolute and functional iron deficiency in professional athletes during training and recovery. <i>International Journal of Cardiology</i> , 2012 , 156, 186-91	3.2	50
189	Plasma adiponectin in heart failure with and without cachexia: catabolic signal linking catabolism, symptomatic status, and prognosis. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014 , 24, 50-6	4.5	49
188	Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2014 , 5, 27-34	10.3	47
187	Cardiac muscle wasting in individuals with cancer cachexia. <i>ESC Heart Failure</i> , 2017 , 4, 458-467	3.7	47
186	Uric acid and xanthine oxidase in heart failure - Emerging data and therapeutic implications. <i>International Journal of Cardiology</i> , 2016 , 213, 15-9	3.2	46
185	Expert opinion paper on atrial fibrillation detection after ischemic stroke. <i>Clinical Research in Cardiology</i> , 2018 , 107, 871-880	6.1	45
184	Chronic heart failure in the very elderly: clinical status, survival, and prognostic factors in 188 patients more than 70 years old. <i>American Heart Journal</i> , 2001 , 142, 174-80	4.9	45
183	The anabolic catabolic transforming agent (ACTA) espidolol increases muscle mass and decreases fat mass in old rats. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2014 , 5, 149-58	10.3	44
182	IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2011 , 2, 105-109	10.3	44
181	Low-dose treatment with atorvastatin leads to anti-oxidative and anti-inflammatory effects in diabetes mellitus. <i>European Journal of Pharmacology</i> , 2007 , 569, 204-11	5.3	44
180	Detection of muscle wasting in patients with chronic heart failure using C-terminal agrin fragment: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). <i>European Journal of Heart Failure</i> , 2015 , 17, 1283-93	12.3	42
179	Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia. <i>International Journal of Cancer</i> , 2012 , 131, 2187-96	7.5	42
178	Immunoadsorption to remove α adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. <i>PLoS ONE</i> , 2018 , 13, e0193672	3.7	41
177	Anorexia, functional capacity, and clinical outcome in patients with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). <i>ESC Heart Failure</i> , 2017 , 4, 448-457	3.7	40
176	Simvastatin reduces wasting and improves cardiac function as well as outcome in experimental cancer cachexia. <i>International Journal of Cardiology</i> , 2013 , 168, 3412-8	3.2	40
175	Anaemia is an independent predictor of death in patients hospitalized for acute heart failure. <i>Clinical Research in Cardiology</i> , 2010 , 99, 107-13	6.1	40
174	Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease. <i>International Journal of Cardiology</i> , 2012 , 162, 27-32	3.2	39

173	Reduced glucose transporter GLUT4 in skeletal muscle predicts insulin resistance in non-diabetic chronic heart failure patients independently of body composition. <i>International Journal of Cardiology</i> , 2010 , 138, 19-24	3.2	39
172	Prediction of mortality in chronic heart failure from peak oxygen consumption adjusted for either body weight or lean tissue. <i>Journal of Cardiac Failure</i> , 2004 , 10, 421-6	3.3	39
171	Twist1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy. <i>International Journal of Cardiology</i> , 2013 , 168, 1447-52	3.2	38
170	Iron status and survival in diabetic patients with coronary artery disease. <i>Diabetes Care</i> , 2013 , 36, 4147-54	4.6	37
169	The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure. <i>Wiener Klinische Wochenschrift</i> , 2009 , 121, 309-13	2.3	37
168	Endothelial dysfunction of the peripheral vascular bed in the acute phase after ischemic stroke. <i>Cerebrovascular Diseases</i> , 2012 , 33, 37-46	3.2	37
167	Whole blood endotoxin responsiveness in patients with chronic heart failure: the importance of serum lipoproteins. <i>European Journal of Heart Failure</i> , 2005 , 7, 479-84	12.3	37
166	Megestrol acetate improves cardiac function in a model of cancer cachexia-induced cardiomyopathy by autophagic modulation. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016 , 7, 555-566	10.3	37
165	Iron deficiency in patients with heart failure with preserved ejection fraction and its association with reduced exercise capacity, muscle strength and quality of life. <i>Clinical Research in Cardiology</i> , 2019 , 108, 203-211	6.1	36
164	Mechanism and novel therapeutic approaches to wasting in chronic disease. <i>Maturitas</i> , 2013 , 75, 199-206	5	36
163	Sarcopenia and Endothelial Function in Patients With Chronic Heart Failure: Results From the Studies Investigating Comorbidities Aggravating Heart Failure (SICA-HF). <i>Journal of the American Medical Directors Association</i> , 2017 , 18, 240-245	5.9	36
162	Elevated plasma levels of neuropeptide proenkephalin A predict mortality and functional outcome in ischemic stroke. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 346-54	15.1	35
161	Cardiac cachexia in early literature: a review of research prior to Medline. <i>International Journal of Cardiology</i> , 2002 , 85, 7-14	3.2	35
160	Increased catabolic activity in adipose tissue of patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2013 , 15, 1131-7	12.3	34
159	The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy. <i>International Journal of Cardiology</i> , 2013 , 168, 3527-31	3.2	34
158	Nutrition in heart failure: an update. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2009 , 12, 384-91	3.8	34
157	Evaluation of C-terminal Agrin Fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016 , 7, 60-7	10.3	34
156	Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial. <i>European Heart Journal</i> , 2020 , 41, 2668-2677	9.5	33

- 155 Uric acid in chronic heart failure. *Seminars in Nephrology*, **2005**, 25, 61-6 4.8 32
- 154 The cardiac component of cardiac cachexia. *American Heart Journal*, **2002**, 144, 45-50 4.9 32
- 153 Iron deficiency in chronic heart failure: case-based practical guidance. *ESC Heart Failure*, **2018**, 5, 764-771 3.7 31
- 152 Cardiac cachexia is associated with right ventricular failure and liver dysfunction. *International Journal of Cardiology*, **2013**, 169, 219-24 3.2 31
- 151 Exercise capacity and body composition in living-donor renal transplant recipients over time. *Nephrology Dialysis Transplantation*, **2009**, 24, 3854-60 4.3 31
- 150 Identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1. *PLoS ONE*, **2011**, 6, e14506 3.7 31
- 149 Influence of diabetes mellitus and hyperglycemia on prognosis in patients > or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). *American Journal of Cardiology*, **2010**, 106, 78-86.e1 3 30
- 148 Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. *Circulation*, **2021**, 144, 1284-1294 16.7 30
- 147 Liver dysfunction and its nutritional implications in heart failure. *Nutrition*, **2013**, 29, 370-8 4.8 29
- 146 Inflammation in right ventricular dysfunction due to thromboembolic pulmonary hypertension. *International Journal of Cardiology*, **2010**, 144, 206-11 3.2 29
- 145 The influence of recovery and training phases on body composition, peripheral vascular function and immune system of professional soccer players. *PLoS ONE*, **2009**, 4, e4910 3.7 29
- 144 Down-regulation of endothelial TLR4 signalling after apo A-I gene transfer contributes to improved survival in an experimental model of lipopolysaccharide-induced inflammation. *Journal of Molecular Medicine*, **2011**, 89, 151-60 5.5 28
- 143 Nutritional status and its effects on muscle wasting in patients with chronic heart failure: insights from Studies Investigating Co-morbidities Aggravating Heart Failure. *Wiener Klinische Wochenschrift*, **2016**, 128, 497-504 2.3 27
- 142 Leukocyte redistribution: effects of beta blockers in patients with chronic heart failure. *PLoS ONE*, **2009**, 4, e6411 3.7 27
- 141 Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. *European Heart Journal - Cardiovascular Pharmacotherapy*, **2019**, 5, 171-180 6.4 26
- 140 Bone marrow iron depletion is common in patients with coronary artery disease. *International Journal of Cardiology*, **2015**, 182, 517-22 3.2 26
- 139 Insulin resistance in heart failure: differences between patients with reduced and preserved left ventricular ejection fraction. *European Journal of Heart Failure*, **2015**, 17, 1015-21 12.3 26
- 138 Elevated levels of asymmetric dimethylarginine in chronic heart failure: a pathophysiologic link between oxygen radical load and impaired vasodilator capacity and the therapeutic effect of allopurinol. *Clinical Pharmacology and Therapeutics*, **2010**, 88, 506-12 6.1 26

137	Wasting of the left ventricle in patients with cardiac cachexia: a cardiovascular magnetic resonance study. <i>International Journal of Cardiology</i> , 2004 , 97, 15-20	3.2	25
136	Muscle wasting as an independent predictor of survival in patients with chronic heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020 , 11, 1242-1249	10.3	25
135	Tandospirone reduces wasting and improves cardiac function in experimental cancer cachexia. <i>International Journal of Cardiology</i> , 2013 , 170, 160-6	3.2	24
134	Cachexia in heart disease: highlights from the ESC 2010. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2011 , 2, 63-69	10.3	22
133	Animal models of cachexia and sarcopenia in chronic illness: Cardiac function, body composition changes and therapeutic results. <i>International Journal of Cardiology</i> , 2017 , 238, 12-18	3.2	21
132	Ursodeoxycholic acid treatment in a rat model of cancer cachexia. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2012 , 3, 31-6	10.3	21
131	Investigation of changes in body composition, metabolic profile and skeletal muscle functional capacity in ischemic stroke patients: the rationale and design of the Body Size in Stroke Study (BoSSS). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2013 , 4, 199-207	10.3	21
130	Hormonal consequences and prognosis of chronic heart failure. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2011 , 18, 224-30	4	21
129	Neurohormonal activation and inflammation in chronic cardiopulmonary disease: a brief systematic review. <i>Wiener Klinische Wochenschrift</i> , 2009 , 121, 293-6	2.3	21
128	Improving exercise capacity and quality of life using non-invasive heart failure treatments: evidence from clinical trials. <i>European Journal of Heart Failure</i> , 2021 , 23, 92-113	12.3	21
127	Body weight changes and incidence of cachexia after stroke. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019 , 10, 611-620	10.3	20
126	Peripheral endothelial dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome. <i>ESC Heart Failure</i> , 2020 , 7, 1064-1071	3.7	20
125	Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2014 , 171, 398-403	3.2	20
124	Intensified secondary prevention intending a reduction of recurrent events in TIA and minor stroke patients (INSPIRE-TMS): a protocol for a randomised controlled trial. <i>BMC Neurology</i> , 2013 , 13, 11	3.1	20
123	Febuxostat improves outcome in a rat model of cancer cachexia. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2015 , 6, 174-80	10.3	20
122	Cellular endotoxin desensitization in patients with severe chronic heart failure. <i>European Journal of Heart Failure</i> , 2005 , 7, 865-8	12.3	20
121	Impact of Plasma Kynurenine Level on Functional Capacity and Outcome in Heart Failure - Results From Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). <i>Circulation Journal</i> , 2016 , 81, 52-61	2.9	19
120	Adiponectin resistance in heart failure and the emerging pattern of metabolic failure in chronic heart failure. <i>Circulation: Heart Failure</i> , 2010 , 3, 181-2	7.6	19

119	Flawed methods and inappropriate conclusions for health policy on overweight and obesity: the Global BMI Mortality Collaboration meta-analysis. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019 , 10, 9-13	10.3	18
118	Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany. <i>ESC Heart Failure</i> , 2017 , 4, 274-281	3.7	18
117	Skeletal muscle weakness is related to insulin resistance in patients with chronic heart failure. <i>ESC Heart Failure</i> , 2015 , 2, 85-89	3.7	18
116	Insulin resistance in chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 239; author reply 239-40	15.1	18
115	Prognostic performance of serial in-hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the MOLITOR study. <i>ESC Heart Failure</i> , 2018 , 5, 288-296	3.7	17
114	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. <i>European Heart Journal</i> , 2021 ,	9.5	17
113	Heart-brain Interactions in Heart Failure. <i>Cardiac Failure Review</i> , 2018 , 4, 87-91	4.2	17
112	The role of cardiologists in stroke prevention and treatment: position paper of the European Society of Cardiology Council on Stroke. <i>European Heart Journal</i> , 2018 , 39, 1567-1573	9.5	16
111	Resting energy expenditure and the effects of muscle wasting in patients with chronic heart failure: results from the Studies Investigating Comorbidities Aggravating Heart Failure (SICA-HF). <i>Journal of the American Medical Directors Association</i> , 2013 , 14, 837-41	5.9	16
110	Effect of application route of the ghrelin analog BIM-28131 (RM-131) on body weight and body composition in a rat heart failure model. <i>International Journal of Cardiology</i> , 2013 , 168, 2369-74	3.2	16
109	Value of serum pregnancy-associated plasma protein A for predicting cardiovascular events among patients presenting with cardiac chest pain. <i>Cmaj</i> , 2013 , 185, E295-303	3.5	16
108	The small intestine: a critical linkage in pathophysiology of cardiac cachexia. <i>International Journal of Cardiology</i> , 2011 , 146, 277-8	3.2	16
107	Uric acid in CHF: marker or player in a metabolic disease?. <i>International Journal of Cardiology</i> , 2007 , 115, 156-8	3.2	16
106	The importance of return to work: How to achieve optimal reintegration in ACS patients. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 1358-1369	3.9	15
105	Rosiglitazone reduces body wasting and improves survival in a rat model of cancer cachexia. <i>Nutrition</i> , 2014 , 30, 1069-75	4.8	15
104	Cardiac cachexia: hic et nunc: "hic et nunc" - here and now. <i>International Journal of Cardiology</i> , 2015 , 201, e1-12	3.2	15
103	Recent developments in the treatment of cachexia: highlights from the 6th Cachexia Conference. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2012 , 3, 45-50	10.3	15
102	The relationship between age and production of tumour necrosis factor-alpha in healthy volunteers and patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2003 , 90, 197-204	3.2	15

101	Critical appraisal of the obesity paradox in cardiovascular disease: how to manage patients with overweight in heart failure?. <i>Heart Failure Reviews</i> , 2014 , 19, 637-44	5	14
100	Risk stratification in patients with chronic heart failure based on metabolic-immunological, functional and haemodynamic parameters. <i>International Journal of Cardiology</i> , 2012 , 156, 62-8	3.2	14
99	Usefulness of minimal modelling to assess impaired insulin sensitivity in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2011 , 147, 47-51	3.2	14
98	Neurological and endocrinological disorders: orphans in chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2011 , 105 Suppl 1, S12-9	4.6	14
97	Heart failure therapy: testosterone replacement and its implications. <i>European Heart Journal</i> , 2006 , 27, 10-2	9.5	13
96	High-sensitivity cardiac troponin T and severity of cerebral white matter lesions in patients with acute ischemic stroke. <i>Journal of Neurology</i> , 2019 , 266, 37-45	5.5	13
95	Sleep-Disordered Breathing in Acute Ischemic Stroke: A Mechanistic Link to Peripheral Endothelial Dysfunction. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	12
94	Micronutrient Depletion in Heart Failure: Common, Clinically Relevant and Treatable. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	11
93	Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: a randomized double-blinded placebo-controlled study. <i>International Journal of Cardiology</i> , 2012 , 161, 137-42	3.2	11
92	Higher serum phosphorus is associated with catabolic/anabolic imbalance in heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2015 , 6, 325-34	10.3	10
91	Mid-regional pro-atrial natriuretic peptide as a prognostic marker for all-cause mortality in patients with symptomatic coronary artery disease. <i>Clinical Science</i> , 2012 , 123, 601-10	6.5	10
90	Uric acid in chronic heart failure--current pathophysiological concepts. <i>European Journal of Heart Failure</i> , 2008 , 10, 1269-70	12.3	10
89	Association of deranged adrenal steroid metabolism with anemia in chronic heart failure. <i>American Journal of Cardiology</i> , 2005 , 96, 101-3	3	10
88	Influence of core body temperature on Tryptophan metabolism, kynurenines, and estimated IDO activity in critically ill patients receiving target temperature management following cardiac arrest. <i>Resuscitation</i> , 2016 , 107, 107-14	4	9
87	Optimizing insulin sensitivity assessment using the minimal model in chronic heart failure. <i>Hormone and Metabolic Research</i> , 2005 , 37, 106-10	3.1	9
86	Defects in insulin action in chronic heart failure. <i>Diabetes, Obesity and Metabolism</i> , 2000 , 2, 203-12	6.7	9
85	Delphi consensus recommendations on how to provide cardiovascular rehabilitation in the COVID-19 era. <i>European Journal of Preventive Cardiology</i> , 2021 , 28, 541-557	3.9	9
84	Could gonadal and adrenal androgen deficiencies contribute to the depressive symptoms in men with systolic heart failure?. <i>Aging Male</i> , 2016 , 19, 221-230	2.1	9

83	Positionspapier zur Detektion von Vorhofflimmern nach ischämischem Schlaganfall. <i>Aktuelle Neurologie</i> , 2018 , 45, 93-106		9
82	Ferric carboxymaltose for the treatment of iron-deficient heart failure patients: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2020 , 7, 3392-3400	3.7	9
81	Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS).. <i>Journal of Translational Medicine</i> , 2022 , 20, 138	8.5	9
80	Lipopolysaccharide responsiveness is an independent predictor of death in patients with chronic heart failure. <i>Journal of Molecular and Cellular Cardiology</i> , 2015 , 87, 48-53	5.8	8
79	Assessment of serum cotinine in patients with chronic heart failure: self-reported versus objective smoking behaviour. <i>Clinical Research in Cardiology</i> , 2013 , 102, 95-101	6.1	8
78	Single baseline serum creatinine measurements predict mortality in critically ill patients hospitalized for acute heart failure. <i>ESC Heart Failure</i> , 2015 , 2, 122-128	3.7	8
77	Furosemide induces mortality in a rat model of chronic heart failure. <i>International Journal of Cardiology</i> , 2012 , 160, 20-5	3.2	8
76	Non-invasive assessment of cardiac hemodynamics in patients with advanced cancer and with chronic heart failure: a pilot feasibility study. <i>Archives of Medical Science</i> , 2013 , 9, 261-7	2.9	8
75	Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and heart failure. <i>Journal of Hypertension</i> , 2016 , 34, 1678-88	1.9	8
74	Effect of exogenous intravenous administrations of GLP-1 and/or GIP on circulating pro-atrial natriuretic peptide in subjects with different stages of glucose tolerance. <i>Diabetes Care</i> , 2015 , 38, e7-8	14.6	7
73	Influence of essential amino acids on muscle mass and muscle strength in patients with cerebral stroke during early rehabilitation: protocol and rationale of a randomized clinical trial (AMINO-Stroke Study). <i>BMC Neurology</i> , 2016 , 16, 10	3.1	7
72	Searching for a relevant definition of sarcopenia: results from the cross-sectional EPIDOS study. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016 , 7, 100-1	10.3	7
71	Impact of chronic inflammatory airway disease on stroke severity and long-term survival after ischemic stroke--a retrospective analysis. <i>BMC Neurology</i> , 2015 , 15, 164	3.1	7
70	Transgenerational transmission of an anticholinergic endophenotype with memory dysfunction. <i>Neurobiology of Aging</i> , 2017 , 51, 19-30	5.6	6
69	The effect of iron deficiency on cardiac resynchronization therapy: results from the RIDE-CRT Study. <i>ESC Heart Failure</i> , 2020 , 7, 1072-1084	3.7	6
68	MT-102 prevents tissue wasting and improves survival in a rat model of severe cancer cachexia. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020 , 11, 594-605	10.3	6
67	Sinus rhythm versus atrial fibrillation in elderly patients with chronic heart failure--insight from the Cardiac Insufficiency Bisoprolol Study in Elderly. <i>International Journal of Cardiology</i> , 2012 , 161, 160-5	3.2	6
66	Anabolic deficiencies in men with systolic heart failure: do co-morbidities and therapies really contribute significantly?. <i>Aging Male</i> , 2013 , 16, 123-31	2.1	6

65	A tissue-specific screen of ceramide expression in aged mice identifies ceramide synthase-1 and ceramide synthase-5 as potential regulators of fiber size and strength in skeletal muscle. <i>Aging Cell</i> , 2020 , 19, e13049	9.9	6
64	Chronic Kidney Disease and Cerebrovascular Disease: Consensus and Guidance From a KDIGO Controversies Conference. <i>Stroke</i> , 2021 , 52, e328-e346	6.7	6
63	The influence of confounders in the analysis of mid-regional pro-atrial natriuretic peptide in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2016 , 219, 84-91	3.2	6
62	Cardiovascular care of patients with stroke and high risk of stroke: The need for interdisciplinary action: A consensus report from the European Society of Cardiology Cardiovascular Round Table. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 682-692	3.9	6
61	Interdisciplinary management of acute ischaemic stroke: Current evidence training requirements for endovascular stroke treatment. Position Paper from the ESC Council on Stroke and the European Association for Percutaneous Cardiovascular Interventions with the support of the European Board of Neurointervention. <i>European Heart Journal</i> , 2021 , 42, 298-307	9.5	6
60	Severe Weight Loss and Its Association with Fatigue in Old Patients at Discharge from a Geriatric Hospital. <i>Nutrients</i> , 2019 , 11,	6.7	5
59	Hand grip strength and fatigability: correlation with clinical parameters and diagnostic suitability in ME/CFS. <i>Journal of Translational Medicine</i> , 2021 , 19, 159	8.5	5
58	Dementia and the heart failure patient. <i>European Heart Journal Supplements</i> , 2019 , 21, L28-L31	1.5	5
57	The importance of rehabilitation in the secondary prevention of cardiovascular disease. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 273-276	3.9	5
56	Longer-term impact of hemiparetic stroke on skeletal muscle metabolism-A pilot study. <i>International Journal of Cardiology</i> , 2017 , 230, 241-247	3.2	4
55	The Obesity Paradigm and Lifetime Risk of Cardiovascular Disease. <i>JAMA Cardiology</i> , 2018 , 3, 895-896	16.2	4
54	Serum phosphorus level is related to degree of clinical response to up-titration of heart failure pharmacotherapy. <i>International Journal of Cardiology</i> , 2014 , 177, 248-54	3.2	4
53	Vasodilation and Exercise Capacity in Patients with End-Stage Renal Disease: A Prospective Proof-of-Concept Study. <i>CardioRenal Medicine</i> , 2016 , 7, 50-59	2.8	4
52	Overview of emerging pharmacotherapy in chronic heart failure. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 2055-74	4	4
51	Weight change with beta-blocker use: a side effect put into perspective. <i>American Journal of Medicine</i> , 2008 , 121, e15; author reply e17	2.4	4
50	Differentiating between body fat and lean mass--how should we measure obesity?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008 , 4, E1; author reply E2		4
49	Personalized anti-thrombotic management of patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 a statement of the ESC Working Group on Cardiovascular Pharmacotherapy and ESC Council on Stroke [corrected]. <i>European Heart Journal</i> , 2021 , 42, 541-543	9.5	4
48	Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1. <i>European Heart Journal</i> , 2019 , 40, 3010-3012	9.5	3

47	The evolving obesity paradigm story: from heart failure to atrial fibrillation. <i>European Heart Journal</i> , 2019 , 40, 1550-1552	9.5	3
46	Late-onset hypogonadism in men with systolic heart failure: prevalence, clinical associates, and impact on long-term survival. <i>ESC Heart Failure</i> , 2014 , 1, 41-51	3.7	3
45	Overweight, obesity, and all-cause mortality. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 1679-80	27.4	3
44	Abnormal serum calcium levels are associated with clinical response to maximization of heart failure therapy. <i>Polish Archives of Internal Medicine</i> , 2015 , 125, 54-64	1.9	3
43	Andropausal syndrome in men with systolic heart failure. <i>Polish Archives of Internal Medicine</i> , 2013 , 123, 156-69	1.9	3
42	Muscle mass, muscle strength, and functional capacity in patients with heart failure of Chagas disease and other aetiologies. <i>ESC Heart Failure</i> , 2020 , 7, 3086-3094	3.7	3
41	Early rehabilitation after stroke: relationship between the heart rate variability and functional outcome. <i>ESC Heart Failure</i> , 2020 , 7, 2983-2991	3.7	3
40	The interpretation of CHA2DS2-VASc score components in clinical practice: a joint survey by the European Heart Rhythm Association (EHRA) Scientific Initiatives Committee, the EHRA Young Electrophysiologists, the Association of Cardiovascular Nursing and Allied Professionals, and the European Society of Cardiology Council on Stroke. <i>Europace</i> , 2021 , 23, 314-322	3.9	3
39	Ischemic Stroke and Heart Failure: Facts and Numbers. An Update. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
38	Intravenous iron supplementation is state of the art therapy in patients with heart failure and iron deficiency. <i>European Journal of Heart Failure</i> , 2019 , 21, 1165	12.3	2
37	Central command in heart failure: was there effect of hemispheric lateralization in insular cortex activation? Reply. <i>European Journal of Heart Failure</i> , 2018 , 20, 1370-1371	12.3	2
36	How to determine a metabolically healthy body composition in cardiovascular disease. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1182-3	15.1	2
35	The impact of body weight on mortality after stroke: the controversy continues. <i>JAMA Neurology</i> , 2015 , 72, 126-7	17.2	2
34	Questions in cardiac resynchronization therapy: metabolic implications. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 591-2; author reply 592	15.1	2
33	Comment on: "Handgrip weakness, low fat-free mass, and overall survival in nonsmall cell lung cancer treated with curative-intent radiotherapy" by Burtin et al. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020 , 11, 1863-1864	10.3	2
32	Comment on: "Experimental ischaemic stroke induces transient cardiac atrophy" by Veltkamp et al. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020 , 11, 1865-1866	10.3	2
31	Relevance of Heart Failure in Prevention, Treatment and Prognosis of Ischemic Stroke. <i>Neurology International Open</i> , 2017 , 1, E61-E64		1
30	Nutrient pattern analysis in critically ill patients using Omics technology (NACHO) - Study protocol for a prospective observational study. <i>Medicine (United States)</i> , 2019 , 98, e13937	1.8	1

29	Heart-brain interactions in patients with heart failure, including takotsubo syndrome: a need to monitor autonomic sympathetic activity: reply. <i>European Journal of Heart Failure</i> , 2018 , 20, 1164-1165	12.3	1
28	Iron deficiency is related to low functional outcome in patients at early rehabilitation after acute stroke.. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022 ,	10.3	1
27	Stroke as Interdisciplinary Disease: What the Practising Cardiologist Can Do18,		1
26	Cardiac Cachexia in Chronic Heart Failure: The Metabolic Facet of CHF 2010 , 165-185		1
25	Acute effects of oral triglyceride load on dynamic changes in peripheral endothelial function in heart failure patients with reduced ejection fraction and healthy controls. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020 , 30, 1961-1966	4.5	1
24	Comment on Weight loss in heart failure is associated with increased mortality only in non-obese patients without diabetes by Niedziela et al. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020 , 11, 1867-1868	10.3	1
23	Tolerability and Efficacy of s.c. IgG Self-Treatment in ME/CFS Patients with IgG/IgG Subclass Deficiency: A Proof-of-Concept Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
22	Expert opinion paper on cardiac imaging after ischemic stroke. <i>Clinical Research in Cardiology</i> , 2021 , 110, 938-958	6.1	1
21	Estimating fat mass in heart failure patients. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2016 , 1, e78-e89	0.9	1
20	Smoking and Other Risk Factors in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2018 , 379, 2572-2573	5.32	1
19	Obesity and long-term outcomes after incident stroke: a prospective population-based cohort study. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021 ,	10.3	1
18	Practical Guidance for Diagnosing and Treating Iron Deficiency in Patients with Heart Failure: Why, Who and How?. <i>Journal of Clinical Medicine</i> , 2022 , 11, 2976	5.1	1
17	Meeting highlights from the 2013 European Society of Cardiology Heart Failure Association Winter Meeting on Translational Heart Failure Research. <i>European Journal of Heart Failure</i> , 2014 , 16, 6-14	12.3	0
16	Comment on Hinnouho et al. Metabolically healthy obesity and risk of mortality: does the definition of metabolic health matter? Diabetes care 2013;36:2294-2300. <i>Diabetes Care</i> , 2014 , 37, e104	14.6	0
15	Anorexia in chronic obstructive pulmonary disease Association to cachexia and hormonal derangement. <i>International Journal of Cardiology</i> , 2009 , 132, 434	3.2	0
14	The role of cardiologists on the stroke unit. <i>European Heart Journal Supplements</i> , 2020 , 22, M3-M12	1.5	0
13	Antithrombotic therapy for stroke prevention in patients with atrial fibrillation who survive an intracerebral haemorrhage: results of an EHRA survey. <i>Europace</i> , 2021 , 23, 806-814	3.9	0
12	Erhalt von Leistungsfähigkeit und Lebensqualität bei chronischer Herzinsuffizienz. <i>Kardiologe</i> , 2022 , 16, 185-196	0.6	0

- 11 Eisenmangel bei Herzinsuffizienz-Patienten. *Klinikerzt*, **2019**, 48, 208-211 0
- 10 Response to the letter to the editor from Xue and Varadhan titled "What is missing in the validation of frailty instruments?". *Journal of the American Medical Directors Association*, **2014**, 15, 147 5.9
- 9 Insulin sensitivity, but not hyperglycemia, may be superior as a prognostic marker and therapeutic target for diabetes in heart failure. *American Journal of Cardiology*, **2012**, 110, 1070; author reply 1070-13
- 8 When a reference value makes all the difference. *Journal of Cachexia, Sarcopenia and Muscle*, **2012**, 3, 141 10.3
- 7 Alterations in Nutrition and Body Mass in Heart Failure **2011**, 330-345
- 6 Losartan: the dose does it. *Expert Opinion on Pharmacotherapy*, **2010**, 11, 2117-9 4
- 5 Letter by Doehner et al regarding article, "Association between obesity and mortality after acute first-ever stroke: the obesity-stroke paradox". *Stroke*, **2011**, 42, e395; author reply e396 6.7
- 4 Survival and body fat in hemodialysis patients: true association or effects of concomitant therapy?. *American Journal of Clinical Nutrition*, **2006**, 84, 663-4; author reply 634 7
- 3 Xanthine Oxidase Inhibitors and Insulin Sensitizers **2005**, 451-472
- 2 Proenkephalin A as Potential Prognostic Biomarker in Acute Ischemic Stroke. *Clinical and Applied Thrombosis/Hemostasis*, **2020**, 26, 1076029620945037 3.3
- 1 Mental involvement in heart failure. *Revista Portuguesa De Cardiologia*, **2021**, 40, 557-559 1